Please ensure Javascript is enabled for purposes of website accessibility

General Electric Sale of Biopharma Unit to Danaher Closes

By Eric Volkman - Mar 31, 2020 at 8:06PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Danaher is paying over $21 billion for the business, which will be renamed Cytiva.

The divestment of a massive healthcare asset by General Electric's (GE 1.30%) life sciences division has been completed. The sale of the biopharma unit of that division to conglomerate Danaher (DHR 2.26%), both companies announced on Tuesday. Furthermore, Danaher wrote in its press release that it will rename the business Cytiva.

The deal between the two companies took quite some time to complete. It was originally announced in February 2019, with Danaher agreeing to pay roughly $21.4 billion in cash for the biopharma unit, around 17 times the anticipated 2019 EBITDA of the unit. Its annual revenue was estimated at $3.2 billion at the time.

A scientist working on a lab sample.

Image source: General Electric

Cytiva will be folded into healthcare-focused Danaher's existing life sciences division, one of its three business segments. When the deal was originally announced, Danaher said of the unit that it "is renowned for providing best-in-class bioprocessing technologies and solutions."

"This acquisition will bring a talented and passionate team as well as a highly innovative, industry-leading product suite to our Life Sciences portfolio, providing an excellent complement to our current biologics workflow solutions," the buyer added.

The deal can be considered to be a win for both parties. Danaher is an acquisitive company that likes to compliment its existing assets. Meanwhile, General Electric has struggled in the recent past and remains eager to sell valuable properties to shore up its finances.

Perhaps because of this, on Tuesday the performances of both companies' shares bettered that of the major stock market indexes. Danaher's fell, but only by 1.7% on the day, while General Electric stock inched up by 0.6%.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

General Electric Company Stock Quote
General Electric Company
$79.93 (1.30%) $1.03
Danaher Corporation Stock Quote
Danaher Corporation
$297.75 (2.26%) $6.57

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/13/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.